- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulation of delafloxacin.
Community acquired pneumonia when other treatment inappropriate
Treatment of skin and skin structure infections
Delafloxacin is indicated in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community acquired pneumonia (CAP) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections.
450mg every 12 hours for a total duration of 5 to 14 days.
450mg every 12 hours for a total duration of 5 to 10 days.
Children under 18 years
End stage renal disease
History of tendon disorder secondary to quinolone use
Precautions and Warnings
Family history of G6PD deficiency
Females of childbearing potential
Patients over 60 years
Predisposition to seizures
Solid organ transplant recipients
Central nervous system disorder
Heart valve disease
History of aneurysm
Reduced seizure threshold
Severe renal impairment
May exacerbate myasthenia gravis
Advise ability to drive/operate machinery may be affected by side effects
Before initiating therapy enquire about previous hypersensitivity reactions
Consult national/regional policy on the use of anti-infectives
Monitor blood glucose closely in patients with diabetes mellitus
Monitor low body weight patients (females <45kg and males <57kg)
Monitor renal function in patients with renal impairment
Advise patient to report mucosal/skin reactions (blistering or peeling)
Advise patient to report signs of neuropathy
Advise patient to seek medical attention if new onset of heart palpitations
Advise patient to seek medical attention in case of acute dyspnoea
Advise patient to seek medical attention in case of developing oedema
Advise pt. to seek medical attention if sudden abdominal,chest or back pain
Consider pseudomembranous colitis if patient presents with diarrhoea
Discontinue at the first sign of tendon inflammation
Discontinue if central nervous disturbances occur
Patients over 60 years are prone to tendon inflammation
Prolonged use may result in superinfection with non-susceptible organisms
Transplant patients are prone to tendon inflammation
Discontinue at once if pseudomembranous colitis occurs
Discontinue if hypersensitivity reactions occur
Female: Ensure adequate contraception during treatment
The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants and those treated concurrently with corticosteroids. Concomitant use of corticosteroids should be avoided. Treatment with delafloxacin should be discontinued and alternative treatment should be considered if signs and symptoms of tendinitis occur (e.g. painful swelling, inflammation).
Patients with a family history of, or actual glucose-6-phosphate dehydrogenase deficiency are prone to haemolytic reactions when treated with other quinolones. Delafloxacin should be used with caution in these patients.
Pregnancy and Lactation
Delafloxacin is contraindicated during pregnancy.
Use of delafloxacin during pregnancy is contraindicated by the manufacturer. Animal studies have shown reproductive toxicity.
Delafloxacin is contraindicated during breastfeeding.
Use of delafloxacin when breastfeeding is contraindicated by the manufacturer. Animal data show that delafloxacin is excreted in breast milk however presence in human breast milk is unknown.
Creatine phosphokinase increased
Decreased serum albumin
Deep vein thrombosis (DVT)
Discolouration of stools
Exacerbation of myasthenia gravis
Gastroesophageal reflux disease
Heart valve regurgitation
Increase in alkaline phosphatase
Increase in serum transaminases
Raised intracranial pressure
Toxic epidermal necrolysis
Urinary tract infections
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2021
Summary of Product Characteristics: Quofenix 450mg tablets. A. Menarini Farmaceutica Internazionale SRL. Revised March 2021.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.